KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

TherapeuticsMD (TXMD) Non-Current Receivables (2022 - 2025)

TherapeuticsMD's Non-Current Receivables history spans 4 years, with the latest figure at $13.7 million for Q4 2025.

  • For Q4 2025, Non-Current Receivables fell 14.35% year-over-year to $13.7 million; the TTM value through Dec 2025 reached $13.7 million, down 14.35%, while the annual FY2025 figure was $13.7 million, 14.35% down from the prior year.
  • Non-Current Receivables reached $13.7 million in Q4 2025 per TXMD's latest filing, down from $14.3 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $20.3 million in Q1 2023 to a low of $13.7 million in Q4 2025.
  • Average Non-Current Receivables over 4 years is $17.2 million, with a median of $17.2 million recorded in 2024.
  • Peak YoY movement for Non-Current Receivables: dropped 8.73% in 2023, then fell 14.35% in 2025.
  • A 4-year view of Non-Current Receivables shows it stood at $20.3 million in 2022, then fell by 8.73% to $18.5 million in 2023, then decreased by 13.38% to $16.0 million in 2024, then dropped by 14.35% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Non-Current Receivables are $13.7 million (Q4 2025), $14.3 million (Q3 2025), and $14.8 million (Q2 2025).